Olfactory disturbance in Parkinson disease.
Singh
Swaraj
S
Schwankhaus
John
J
D000368:Aged; D000927:Anticonvulsants / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D014150:Antipsychotic Agents / Q000627:therapeutic use; D000068180:Aripiprazole; D015415:Biomarkers; D001921:Brain / Q000187:drug effects / Q000503:physiopathology; D003072:Cognition Disorders / Q000175:diagnosis / Q000209:etiology / Q000523:psychology; D003248:Constipation / Q000209:etiology; D003937:Diagnosis, Differential; D018450:Disease Progression; D004569:Electroencephalography; D006212:Hallucinations / Q000188:drug therapy / Q000209:etiology* / Q000503:physiopathology*; D006801:Humans; D000077287:Levetiracetam; D020961:Lewy Body Disease / Q000150:complications / Q000473:pathology / Q000503:physiopathology; D008297:Male; D009833:Olfactory Pathways / Q000187:drug effects / Q000503:physiopathology*; D010300:Parkinson Disease / Q000150:complications* / Q000523:psychology*; D010879:Piperazines / Q000627:therapeutic use; D010889:Piracetam / Q000031:analogs & derivatives / Q000627:therapeutic use; D015363:Quinolones / Q000627:therapeutic use; D020187:REM Sleep Behavior Disorder / Q000209:etiology; D017211:Treatment Failure; D014202:Tremor / Q000188:drug therapy / Q000209:etiology
D000927:Anticonvulsants; D000978:Antiparkinson Agents; D014150:Antipsychotic Agents; D015415:Biomarkers; D010879:Piperazines; D015363:Quinolones; D000077287:Levetiracetam; D000068180:Aripiprazole; D010889:Piracetam